Amgen’s experimental Sjogren’s drug meets late-stage trial goal

Nov 11 (Reuters) – Amgen ​said ‌on Wednesday ‌its ​experimental ⁠drug showed ⁠sustained reduction in ​disease ⁠activity ⁠in ​a late-stage ​study of ‌patients with ⁠Sjogren’s disease, an ⁠autoimmune ‌condition.

(Reporting ⁠by ​Kamal ‌Choudhury ​in Bengaluru; ⁠Editing by Shilpi ​Majumdar)